[Telaprevir-benefit assessment of the Institute for Quality and Efficiency in Health Care (IQWiG) in accordance with § 35a SGB V (dosing evaluation)]

MeSH terms

• Dose-Response Relationship, Drug
• Evidence-Based Medicine*
• Gastroenterology / standards*
• Germany
• Hepatitis C / drug therapy*
• Humans
• Oligopeptides / administration & dosage*
• Oligopeptides / adverse effects
• Practice Guidelines as Topic*
• Treatment Outcome